Houman David Hemmati MD, PhD

Houman David Hemmati MD, PhD has a diverse work experience in the medical field. Houman David is currently serving as the Chief Medical Officer at Vyluma since May 2021. Prior to this, they co-founded Levation Pharma, Ltd. in 2017 and held the position of Chief Scientific Officer. Houman David is also a member of the Board of Directors at Trailhead Biosystems Inc. and MediPrint Ophthalmics since November 2020. In addition, Dr. Hemmati has worked as a Senior Ophthalmology Investment & Development Advisor at Novateur Ventures Inc. since June 2017.

Before their involvement with these companies, Dr. Hemmati worked as an Adjunct Clinical Assistant Professor of Ophthalmology at Keck Medicine of USC from December 2014 to December 2020. Houman David also served as the Vice President of Medical and Clinical Development for New Therapies at Capricor Therapeutics, Inc. from June 2015 to May 2017. During their time at Capricor Therapeutics, they led and directed strategic, pre-clinical, and clinical efforts for the development of biologic products, with a focus on the CAP-2003 exosome platform, and spearheaded global patient advocacy and clinical trial recruitment for orphan/rare disease indications.

Prior to their industry roles, Dr. Hemmati worked at Allergan as a Director of Clinical Development from July 2013 to June 2015, where they contributed to various anterior segment ophthalmology clinical development programs and served as a member of the cross-functional Independent Review Team. Houman David also conducted due diligence for ophthalmic drug delivery in-licensing opportunities.

Earlier in their career, Dr. Hemmati served as an Assistant Professor of Ophthalmology at The Robert Larner, M.D. College of Medicine at The University of Vermont from July 2012 to June 2013. Houman David completed their Cornea & Refractive Surgery Fellowship at Harvard Medical School's Department of Ophthalmology from July 2010 to July 2012, where they gained expertise in various refractive surgery platforms and specialized in cataract surgeries in eyes with preexisting corneal diseases.

Overall, Dr. Hemmati's work experience encompasses roles in leadership, scientific research, and clinical development, reflecting their wide-ranging expertise in ophthalmology and biotechnology.

Houman David Hemmati MD, PhD completed their education in a chronological order. Houman David began their academic journey at North Hollywood High School, where they studied from 1990 to 1993. Following this, they pursued their undergraduate degree at Stanford University from 1993 to 1996, majoring in Biological Sciences and earning a Bachelor of Science (BS) degree.

Continuing their education, Hemmati joined the California Institute of Technology (Caltech) from 1999 to 2004. During this period, they obtained their PhD, focusing on an undisclosed field of study. Moving forward, Hemmati enrolled at the David Geffen School of Medicine at UCLA from 1997 to 2006. Here, they completed their Doctor of Medicine (M.D.) degree.

In addition to their academic pursuits, Hemmati also acquired several certifications. Houman David obtained a Controlled Substance Registration Certificate from the United States Drug Enforcement Administration (DEA) in September 2012. Subsequently, in April 2013, they acquired a California Medical License from the Medical Board of California. Additionally, they are Board Certified by the American Board of Ophthalmology, although the institution from which they received this certification was not specified.

Based on the provided information, no assumptions can be made that go beyond Hemmati's educational and certification history.